The cardiovascular and weight-modifying benefits of GLP-1 agonists and SGLT2 inhibitors represent significant advancements in the therapy of T2DM, providing patients with additional therapeutic options beyond traditional antihyperglycemic agents. This evidence concerns the gene GCG and type 2 diabetes mellitus.